Compare FNLC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNLC | CBIO |
|---|---|---|
| Founded | 1864 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 340.4M |
| IPO Year | 1995 | N/A |
| Metric | FNLC | CBIO |
|---|---|---|
| Price | $29.26 | $18.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 15.2K | ★ 219.7K |
| Earning Date | 04-22-2026 | 05-23-2026 |
| Dividend Yield | ★ 5.15% | N/A |
| EPS Growth | ★ 26.34 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $355.04 |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.11 | $8.72 |
| 52 Week High | $30.33 | $20.58 |
| Indicator | FNLC | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 77.93 |
| Support Level | $26.25 | $10.89 |
| Resistance Level | $30.33 | N/A |
| Average True Range (ATR) | 0.71 | 1.57 |
| MACD | 0.13 | 0.79 |
| Stochastic Oscillator | 65.88 | 85.30 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.